FN-D regimen: Difference between revisions
(Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}}Fludarabine-Novantrone-Dexamethasone Regimen; FMD Regimen; FND Regimen ==Overview== {{PAGENAME}} refers to a regimen consisting...") |
No edit summary |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[fludarabine]], [[mitoxantrone]] and [[dexamethasone]] used to treat indolent [[non-Hodgkin's lymphoma]] and rituximab in combination is used for the treatment of advanced [[follicular lymphoma]]<ref name="pmid23960180">{{cite journal| author=Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F, Tucci A et al.| title=Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. | journal=J Clin Oncol | year= 2013 | volume= 31 | issue= 27 | pages= 3351-9 | pmid=23960180 | doi=10.1200/JCO.2012.44.8290 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23960180 }} </ref> | {{PAGENAME}} refers to a regimen consisting of [[fludarabine]], [[mitoxantrone]] and [[dexamethasone]] used to treat indolent [[non-Hodgkin's lymphoma]] and rituximab in combination is used for the treatment of advanced [[follicular lymphoma]]<ref name="pmid23960180">{{cite journal| author=Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F, Tucci A et al.| title=Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. | journal=J Clin Oncol | year= 2013 | volume= 31 | issue= 27 | pages= 3351-9 | pmid=23960180 | doi=10.1200/JCO.2012.44.8290 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23960180 }} </ref><ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63454}}</ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|F|Fludarabine}} | |||
{{chemo|N|Novantrone (mitoxantrone)}} | {{chemo|N|Novantrone (mitoxantrone)}} | ||
| Line 16: | Line 16: | ||
==Indications== | ==Indications== | ||
*[[Non-Hodgkin's lymphoma]]<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63454}}</ref><ref name="pmid23960180">{{cite journal| author=Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F, Tucci A et al.| title=Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. | journal=J Clin Oncol | year= 2013 | volume= 31 | issue= 27 | pages= 3351-9 | pmid=23960180 | doi=10.1200/JCO.2012.44.8290 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23960180 }} </ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Chemotherapy regimens]] | [[Category:Chemotherapy regimens]] | ||
Latest revision as of 18:03, 26 March 2015
|
WikiDoc Resources for FN-D regimen |
|
Articles |
|---|
|
Most recent articles on FN-D regimen Most cited articles on FN-D regimen |
|
Media |
|
Powerpoint slides on FN-D regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on FN-D regimen at Clinical Trials.gov Clinical Trials on FN-D regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on FN-D regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on FN-D regimen Discussion groups on FN-D regimen Patient Handouts on FN-D regimen Directions to Hospitals Treating FN-D regimen Risk calculators and risk factors for FN-D regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for FN-D regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:Fludarabine-Novantrone-Dexamethasone Regimen; FMD Regimen; FND Regimen
Overview
FN-D regimen refers to a regimen consisting of fludarabine, mitoxantrone and dexamethasone used to treat indolent non-Hodgkin's lymphoma and rituximab in combination is used for the treatment of advanced follicular lymphoma[1][2]
Regimen
FFludarabine
NNovantrone (mitoxantrone)
DDexamethasone
Indications
References
- ↑ 1.0 1.1 Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F, Tucci A; et al. (2013). "Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi". J Clin Oncol. 31 (27): 3351–9. doi:10.1200/JCO.2012.44.8290. PMID 23960180.
- ↑ "NCI Thesaurus".
- ↑ "NCI Thesaurus".